This interactive section of The New York Times website shares stories of patients with Sjögren Syndrome. Over 20 percent of patients with systemic sclerosis and a few with localized scleroderma also have Sjögren Syndrome. It is more often detected in persons with the limited form of systemic sclerosis. The symptoms and examination findings and methods of diagnosis and treatment in Sjögren Syndrome in scleroderma patients are identical to those in primary Sjögren Syndrome.
Join us for a free webinar in the comfort of your
own home hosted by Dr. Dinesh Khanna from the University of Michigan on
Managing GI Involvement. There is no sign-up necessary. Join the meeting here just prior
to the start time.
Discovery Documentary: First in Human
Final episode Thursday evening August 24 at 9:00 p.m. ET/PT on Discovery.
First in Human is a three-part documentary
capturing the real-life experiences of doctors, researchers, staff,
patients and their caregivers, at the NIH Clinical Center.* The
documentary airs on three sequential Thursday evenings
on August 10, 17, and 24, at 9:00 p.m. ET/PT on Discovery.
Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis
Genentech has completed enrollment for a Phase III
clinical trial investigating the use of Actemra (tocilizumab) in
patients with systemic sclerosis (also known as scleroderma). Overall,
211 patients were enrolled just over 15 months in
106 activated sites around the world.
Genentech announced that the FDA granted
Breakthrough Therapy Designation to Actemra for the treatment of
systemic sclerosis at EULAR 2015, during which Phase II data were
presented and the initiation of the Phase III clinical trial was
also announced. Follow the link below to read the original press release regarding the Breakthrough Therapy Designation.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.